20/01/2021 – AI3SD Winter Seminar Series: ML 4 Scientific Discovery
This seminar was the fourth of ten in our AI3SD Winter Seminar Series. This seminar was hosted online via a zoom webinar. The event was themed around ML for Scientific…
This seminar was the fourth of ten in our AI3SD Winter Seminar Series. This seminar was hosted online via a zoom webinar. The event was themed around ML for Scientific…
We are delighted to share our perspectives publication with you, explaining the philosophical, scientific, and technical underpinnings of the Network and detailing its inception and the first year of activity.…
This seminar was the third of ten in our AI3SD Winter Seminar Series. This seminar was hosted online via a zoom webinar. The event was themed around Enhancing Experiments through…
This seminar forms part of the AI3SD Online Seminar Series that will run across the winter (from November 2020 to April 2021). This seminar will be run via zoom, when you register on Eventbrite you will receive a zoom registration email alongside your standard Eventbrite registration email. Where speakers have given permission to be recorded, their talks will be made available on our AI3SD YouTube Channel. The theme for this seminar is Enhancing Experiments through Machine Learning.
This seminar was the second of ten in our AI3SD Winter Seminar Series. This seminar was hosted online via a zoom webinar. The event was themed around Enhancing Experiments through…
This seminar forms part of the AI3SD Online Seminar Series that will run across the winter (from November 2020 to April 2021). This seminar will be run via zoom, when you register on Eventbrite you will receive a zoom registration email alongside your standard Eventbrite registration email. Where speakers have given permission to be recorded, their talks will be made available on our AI3SD YouTube Channel. The theme for this seminar is Robots, AI and NLP in Drug Discovery.
There is now broad recognition within the scientific community that the ongoing deluge of scientific data is fundamentally transforming academic research. Turing Award winner Jim Gray referred to this revolution as “The Fourth Paradigm: Data Intensive Scientific Discovery’. Researchers now need tools and technologies to manipulate, analyze, visualize, and manage vast amounts of research data. This talk will begin by reviewing the challenges posed by the explosive growth of experimental and observational data generated by large-scale facilities such as the Diamond Synchrotron and the CryoEM Facilities at the Rutherford Appleton Laboratory. Increasingly, scientists are beginning to use sophisticated machine learning and other AI technologies both to automate parts of the data pipeline and also to find new scientific discoveries in the deluge of experimental data. In particular, ‘Deep Learning’ neural networks have already transformed several areas of computer science and research scientists are now exploring their use in analyzing their ‘Big Scientific Data’. The talk concludes with a vision of how this ‘AI for Science’ agenda can be truly transformative for experimental scientific discovery.
Since the 1980’s the development of novel antibiotics has dramatically reduced. This, combined with the ever-increasing prevalence of antibiotic resistance in bacteria, means that some bacterial strains have now been identified that are resistant to treatment with all known classes of antibiotic currently available. Supramolecular Self-associating Amphiphiles (SSAs) are a novel class of amphiphilic salts that contain an uneven number of covalently linked hydrogen bond donating and accepting groups, meaning that they are ‘frustrated’ in nature. The hydrogen-bonded, self-associative properties for members of this class of over 70 compounds synthesised to date have been extensively studied in the gas phase, solution state, solid state and in silico. Through these studies we have shown correlations between certain physicochemical properties that maybe predicted by simple, low-level, high-throughput, easily accessible computational modelling. In addition, members from this class of compound have been shown to kill a variety of different bacteria, including those with known antibiotic resistance (e.g. Methicillin Resistant Staphylococcus aureus (MRSA)). These initial studies have highlighted within the supramolecular chemistry community a vast amount of experimental data, not yet accessed by AI/machine learning. Could data sets such as these be the next targets of interest for this community? Is there room for a consortium or community led approach to solving predictive modelling within this branch of chemistry.
he concept of in silico molecular design goes back decades and has a long history of published approaches using many different algorithms and models. Major challenges involved in de novo molecular design are manifold, including identifying appropriate molecular representations for optimisation, scoring designed molecules against multiple modelled endpoints, and objectively quantifying synthetic feasibility of the designed structures. Recently, multiobjective de novo design, more recently referred to as generative chemistry, has had a resurgence of interest. This renaissance has highlighted a step-change in successful applications of such methods. This presentation will review the development of de novo design methods over the years including the author’s original work in this area from the early 2000s, to recent approaches that show great promise. Through this review, improvements in important components of de novo design, including machine learning model predictions and automated synthesis planning, will also be presented.
Professor Charlotte Deane from the University of Oxford speaks about some of the work her research group have done on Machine Learning for Early Stage Drug Discovery to give a flavour of the different kinds of approaches they have been looking at. These run from predicting whether molecules will bind or not bind to a given protein target, to trying to remove biases from that kind of work, to finally how do we generate novel molecules in the protein binding sites.